Loading data for ATAI — first visit, this takes a few seconds.

알림

AtaiBeckley Inc. (ATAI)

NasdaqGM: ATAI · 실시간 가격 · USD

7.35

-0.04 (-0.54%)

종가 기준: Aug 27, 2026, 8:00 PM

7.31

-0.53%

프리마켓: 6:06 AM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.54% (1D)

데이터 없음

매수호가	7.17
시가총액	2.73B
매출 (ttm)	4.47M
순이익 (ttm)	-668.19M
	1.55
	-2.79
	n/a
	-15
P/B (ttm)	15.38
P/S (ttm)	609.54
실적 발표일	Nov 12, 2026

매도호가	7.2
거래량	3,033,385
평균 거래량 (20일)	12,086,406
시가	7.38
전일 종가	7.39
일중 범위	7.35 - 7.40
52주 범위	3.27 - 7.45
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ATAI 소개

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 18, 2021

직원 수 99

상장 거래소 NasdaqGM

티커 ATAI

웹사이트 https://www.ataibeckley.com

전체 기업 정보

재무 실적

2025년 AtaiBeckley의 매출은 4.09M로, 전년 308K 대비 1,227.6% 증가했습니다. 순이익은 -660.05M로, 342.19% 증가했습니다.

재무제표

어닝 서프라이즈

AtaiBeckley가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $954K 예상치 하회 $0, 및 -38.65% 전년 대비 감소.
EPS -0.09 예상치 상회 0.02, 및 40.00% 전년 대비 성장.

다음 실적 발표

AtaiBeckley Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Simply Wall St.

3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now

Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

3주 전 · Zacks

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

3주 전 · Barrons.com

Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications, though one glaring question hung over the print. The world’s biggest drugmaker by mar...

3주 전 · Market Exclusive

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Vireo Growth to Acquire Planet 13 in Landmark All-Stock Deal SNDL Completed Parallel Asset Acquisition, Expanding its U.S. Medical Cannabis Footprint Tilray Posted Recor...

1개월 전 · IPO-Edge.com

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Sil...

2 페이지 중 1

AtaiBeckley Inc. (ATAI)